X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (80653) 80653
Newsletter (323) 323
Newspaper Article (237) 237
Magazine Article (89) 89
Book Chapter (76) 76
Book / eBook (33) 33
Dissertation (26) 26
Trade Publication Article (20) 20
Publication (7) 7
Web Resource (7) 7
Conference Proceeding (6) 6
Transcript (4) 4
Streaming Video (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (63556) 63556
oncology (40663) 40663
female (34954) 34954
male (32343) 32343
middle aged (28458) 28458
aged (26401) 26401
cancer (25526) 25526
lung neoplasms - drug therapy (19756) 19756
lung neoplasms - pathology (19526) 19526
lung cancer (19349) 19349
carcinoma, non-small-cell lung - drug therapy (19194) 19194
adult (18097) 18097
chemotherapy (18044) 18044
carcinoma, non-small-cell lung - pathology (16167) 16167
prognosis (16018) 16018
tumors (14231) 14231
carcinoma (13823) 13823
metastasis (13817) 13817
lung cancer, non-small cell (11700) 11700
expression (11398) 11398
neoplasm staging (11358) 11358
aged, 80 and over (11168) 11168
care and treatment (11029) 11029
survival (10953) 10953
cell line, tumor (10474) 10474
apoptosis (10452) 10452
animals (10291) 10291
treatment outcome (9998) 9998
research (9880) 9880
lung neoplasms - genetics (8879) 8879
analysis (8823) 8823
cancer therapies (8657) 8657
antineoplastic combined chemotherapy protocols - therapeutic use (8453) 8453
lung neoplasms - mortality (8201) 8201
carcinoma, non-small-cell lung - genetics (8186) 8186
gene expression (8085) 8085
medical prognosis (7714) 7714
mutation (7695) 7695
non-small cell lung cancer (7611) 7611
surgery (7577) 7577
proteins (7542) 7542
carcinoma, non-small-cell lung - mortality (7430) 7430
respiratory system (7388) 7388
patients (7220) 7220
antineoplastic agents - therapeutic use (7210) 7210
health aspects (7008) 7008
radiotherapy (6866) 6866
genetic aspects (6862) 6862
retrospective studies (6850) 6850
immunohistochemistry (6584) 6584
mice (6425) 6425
survival analysis (6270) 6270
non-small cell lung carcinoma (6266) 6266
survival rate (6090) 6090
lung neoplasms - metabolism (6058) 6058
cell biology (6010) 6010
development and progression (5979) 5979
therapy (5946) 5946
kinases (5909) 5909
medicine & public health (5739) 5739
lung neoplasms - therapy (5553) 5553
metastases (5421) 5421
adenocarcinoma (5346) 5346
cisplatin (5340) 5340
breast-cancer (5265) 5265
lung neoplasms - radiotherapy (5235) 5235
gene expression regulation, neoplastic (5192) 5192
studies (5145) 5145
carcinoma, non-small-cell lung - metabolism (5140) 5140
squamous cell carcinoma (5114) 5114
carcinoma, non-small-cell lung - therapy (5040) 5040
carcinoma, non-small-cell lung - radiotherapy (5034) 5034
lung neoplasms - surgery (4973) 4973
hematology, oncology and palliative medicine (4867) 4867
cell proliferation (4823) 4823
disease-free survival (4795) 4795
pathology (4793) 4793
lung-cancer (4788) 4788
cell lung-cancer (4713) 4713
medicine (4708) 4708
biomarkers (4688) 4688
carcinoma, non-small-cell lung - surgery (4461) 4461
research article (4408) 4408
breast cancer (4316) 4316
signal transduction (4305) 4305
pharmacology & pharmacy (4216) 4216
combined modality therapy (4209) 4209
antineoplastic agents - pharmacology (4205) 4205
radiology, nuclear medicine & medical imaging (4177) 4177
gefitinib (4161) 4161
diagnosis (4155) 4155
cell cycle (4039) 4039
growth (4029) 4029
immunotherapy (3989) 3989
cancer research (3982) 3982
multidisciplinary sciences (3967) 3967
nsclc (3915) 3915
follow-up studies (3907) 3907
biochemistry & molecular biology (3898) 3898
medicine, research & experimental (3898) 3898
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (11) 11
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (10) 10
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Toronto East General Hospital - Online (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (79013) 79013
Chinese (899) 899
Japanese (851) 851
French (785) 785
German (511) 511
Spanish (89) 89
Italian (88) 88
Portuguese (87) 87
Polish (85) 85
Russian (77) 77
Czech (39) 39
Hungarian (38) 38
Dutch (29) 29
Korean (27) 27
Turkish (22) 22
Serbian (15) 15
Danish (13) 13
Norwegian (11) 11
Romanian (11) 11
Finnish (8) 8
Croatian (5) 5
Hebrew (5) 5
Lithuanian (4) 4
Swedish (4) 4
Slovak (3) 3
Bulgarian (2) 2
Icelandic (2) 2
Slovenian (2) 2
Arabic (1) 1
Bosnian (1) 1
Greek (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
Clinical cancer research, ISSN 1557-3265, 2018, Volume 24, Issue 14, pp. 3334 - 3347
Purpose: Despite initial benefit from tyrosine kinase inhibitors (TKIs), patients with advanced non-small cell lung cancer (NSCLC) harboring ALK (ALK(+)) and ROS1 (ROS1... 
MUTATION CONFERS RESISTANCE | ONCOLOGY | OVERCOMES CRIZOTINIB RESISTANCE | EML4-ALK FUSION | COPY NUMBER | IN-SITU HYBRIDIZATION | GENE REARRANGEMENT | LYMPHOMA KINASE ALK | TUMOR-CELLS | INHIBITOR | NSCLC PATIENTS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Molecular Targeted Therapy | Biomarkers, Tumor | Anaplastic Lymphoma Kinase - genetics | DNA Copy Number Variations | Young Adult | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - chemistry | Protein-Tyrosine Kinases - chemistry | Adult | Female | Anaplastic Lymphoma Kinase - chemistry | Lung Neoplasms - genetics | Computational Biology - methods | Carcinoma, Non-Small-Cell Lung - genetics | Models, Molecular | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Drug Resistance, Neoplasm - genetics | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | High-Throughput Nucleotide Sequencing | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung Neoplasms - diagnosis | Tyrosine | Neuregulin 1 | Epidermal growth factor receptors | Genes | Lung cancer | Non-small cell lung carcinoma | Drug resistance | Kinases | Patients | ErbB-2 protein | Gene fusion | Genetic screening | Gene sequencing | Polymerase chain reaction | β-catenin | Ret protein | Experimental design | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | DNA sequencing | Cancer | Proto-oncogenes | non-small cell lung cancer | ALK | tyrosine kinase inhibitor | ROS1 | acquired resistance
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 9, pp. 829 - 838
...–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse. 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2011, Volume 103, Issue 19, pp. 1452 - 1460
Background The combination of chemotherapy with thoracic radiotherapy (TRT) compared with TRT alone has been shown to confer a survival advantage for good performance status patients with stage III non-small cell lung cancer... 
IRRADIATION | CARBOPLATIN | CISPLATIN | VINORELBINE | ONCOLOGY | THERAPY-ONCOLOGY-GROUP | CHEMORADIOTHERAPY | RADIOTHERAPY | CHEMOTHERAPY | RADIATION-THERAPY | PACLITAXEL | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Time Factors | Vinblastine - adverse effects | Aged, 80 and over | Adult | Dose Fractionation | Chemotherapy, Adjuvant | Odds Ratio | Radiotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Radiotherapy Dosage | Etoposide - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Disease Progression | Canada | Confounding Factors (Epidemiology) | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Etoposide | Research | Lung cancer, Non-small cell | Drug therapy | Radiotherapy | Health aspects | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 13, pp. 1189 - 1197
...–small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 5% of cases. 2 – 8 ALK -rearranged tumors depend on ALK for growth and survival and show marked sensitivity to ALK inhibitors such as crizotinib... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 2011, Volume 81, Issue 5, pp. 1352 - 1358
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation (T790M... 
TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | MUTATIONS | AFATINIB | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article